Pharmaxis (PXS)

Shares / Stock Code

PXS

Stock Exchange / Sharemarket

ax

Pharmaxis (PXS) is a pharmaceutical company specialising in the research, development and commercialisation of therapeutic pharmaceutical products. The Company manufactures specialty products for use in the diagnosis and treatment of chronic respiratory and immune disorders. Pharmaxis was listed on the Australian Stock Exchange on 10th November, 2003. Pharmaxis is based in Sydney, with offices also in the US, UK and China. It listed on the on NASDAQ (symbol PXSL) in August 2005. The company's products include Aridol targeting asthma; Bronchitol for the treatment of cystic fibrosis and chronic obstructive pulmonary disease; PXS25/64 for the treatment of multiple sclerosis; and PXS2076 targeting rheumatoid arthritis. Aridol is used to diagnose and manage asthma and chronic obstructive pulmonary disease (COPD). The Aridol test imitates the bronchoconstriction occurring in inflamed airways during asthma episodes. It may also be used to find out the appropriate doses of inhaled corticosteroid needed for controlling asthma. The Company gained the approval for the sale of Aridol in Australia in March 2006. Pharmaxis began the marketing of Aridol commercially in Australia in June 2006. PXS also markets Aridol to major European countries and Korea. Bronchitol is in final clinical trials and it targets cystic fibrosis and chronic obstructive pulmonary disease. The Company aims at bringing its therapeutic advances for respiratory and immune diseases to patients worldwide, and to become a market leader in the international pharmaceutical business. The Company’s manufacturing facilities are TGA-approved and PXS is one of the largest life sciences companies in Australia.

Pharmaxis History

Pharmaxis is a Sydney based pharmaceutical company established in 1998. The company operates a manufacturing facility in Frenchs Forest, Sydney and a research facility at the John Curtin School of Medical Research at the Australian National University in Canberra. In 2001, Pharmaxis licensed patents for respiratory products from technology developed by Royal Prince Alfred Hospital based in Sydney. In 2002, the Company established Frenchs Forest facility and listed on the ASX in November 2003 under the code PXS. The Company received licensing for its manufacturing facility in 2003 by TGA and commenced production. It listed on the NASDAQ in 2005 under the symbol PXSL. In 2006 the Company gained approval for the sale and marketing of its product Aridol, in Sweden and Australia. In 2007, PXS received EU approval for the marketing of Aridol to 13 European countries. The Company established its European headquarters in UK in 2007. In 2008 Pharmaxis commenced construction on new factory and headquartered in Frenchs Forest. In 2008 Aridol gained approval in Korea and in all major European countries and it was accepted by Olympic Committee Aridol for elite athletes.